Mandate

VINGE ADVISES SHANGHAI XINGXUEKANG IVESTMENT PARTNERSHIP IN CONNECTION WITH THE ACQUISITION OF OPCON ENERGY SYSTEMS SVENSAK ROTORMASKINER

July 02, 2015

XingXueKang Investment Partnership has entered into a share purchase agreement with Opcon, the energy and environmental technology group a share purchase agreement concerning the sale of Opcon’s main part of the group’s operations within compressor technology and waste heat recovery. The transaction also includes the newly-formed company, Opcon Compressor Technology AB as well as the subsidiaries Svenska Rotor Maskiner AB, Opcon Energy System AB and 48.9796% of the shares in the jointly owned Chinese company Fuijan Opcon Energy Technology Co. Ltd. The transaction also includes all intellectual property rights related to compressor technology and Opcon Powerbox. The Opcon trademark will also be assigned although it will continue to be used by the Opcon group during a transitional period.

Following completion of the due diligence phase based on the accounts as per 31 March 2015, the purchase price amounts to SEK 400 million. Fifteen per cent of the purchase price will be paid in cash not later than 20 business days after the agreement enters into force following approval by the members at Opcon’s general meeting and approval by the investment committee which controls the purchaser. The remaining 85% of the purchase price shall be paid at closing of the transaction, which is anticipated to occur on 30 September 2015 when title to the shares passes to the purchaser.

Vinge’s team consisted of responsible counsel Qun Gu and Ulrich Ziche (project manager), and Andrea Jägerstedt (M&A), Johan Cederblad, Niclas Winnberg and Julia Nääs (real estate and environmental), Karin Grauers (commercial agreements, IP and IT), Maria Schultzberg (tax), Johan Wahlbom (competition) and project assistants Annika Johnson and Carline Skymberg.

For further information, please see Opcon’s press release: www.opcon.se

Related

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).
July 18, 2025

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025